Corline Heparin Surface coating receives first-ever Canadian regulatory approval for use in Kardium’s Globe PFA catheter
Executive summary: Kardium’s Globe Catheter with Corline Heparin Surface (CHS™) coating received regulatory approval in Canada on August 10, 2026, marking the first approval of this coating in a medical device in the country. The approval validates the CHS™ coating’s efficacy in reducing thrombotic risks during Pulsed Field Ablation procedures, enabling commercialization in Canada and signaling readiness for broader North American market entry.
Who is involved: Kardium (medical device developer), Corline Biomedical (coating technology provider), Canadian regulatory authorities (likely Health Canada).
Likely next: Kardium will pursue commercial launch in Canada, seek additional regulatory clearances (e.g., FDA, CE), and expand clinical evidence to support wider adoption of CHS™-coated PFA catheters.
Kardium announced that its Globe Catheter, featuring Corline’s Heparin Surface (CHS™) coating, has received regulatory approval in Canada, marking the first time this specific anticoagulant coating is part of an approved medical device in the country. The Globe Catheter is designed for Pulsed Field Ablation (PFA), a non-thermal atrial fibrillation treatment. This approval validates the safety and efficacy of the CHS™ coating in reducing thrombus formation during ablation procedures. The development strengthens Kardium’s position in the growing PFA market and supports Corline’s expansion into North American medical device partnerships.
Timeline
- — Kardiums Globe-kateter med CHS™-coatning erhåller godkännande i Kanada (GlobeNewswire)
Analysis — what this means
Likely next events
- Kardium to initiate Canadian market launch of Globe Catheter by Q4 2026
- FDA submission for Globe Catheter with CHS™ coating expected by Q1 2027
- Corline to report Q3 2026 revenue impact from Kardium partnership by October 2026
- First real-world efficacy data from Canadian PFA procedures using Globe Catheter anticipated by mid-2027
Sectors affected
- Medical devices
- Cardiac ablation
- Antimicrobial coatings
- Atrial fibrillation treatment
Regulatory implications
- CHS™ coating now cleared as part of a Class III medical device in Canada under Medical Devices Regulations
- Approval supports future 510(k) or PMA pathways in the U.S. FDA for similar coating-device combinations
- Establishes precedent for heparin-based coatings in energy-based ablation devices
Historical parallels
- Approval of heparin-coated catheters in U.S. (e.g., Medtronic’s Attain OTW, 2008)
- First drug-eluting stent approval (Cypher, 2003) – parallel in combining device with bioactive coating
- FDA approval of Boston Scientific’s Watchman FLX with hemocompatible coating (2020)
Key entities
Sources
Open the full interactive case file on Beyond →